Welcome to our dedicated page for Blueprint Medicines news (Ticker: BPMC), a resource for investors and traders seeking the latest updates and insights on Blueprint Medicines stock.
Blueprint Medicines Corporation (BPMC) pioneers targeted kinase therapies for genetically defined cancers and rare disorders. This dedicated news hub provides stakeholders with comprehensive updates on the company's scientific advancements, regulatory progress, and strategic initiatives.
Access verified information about clinical trial results, FDA submissions, partnership announcements, and financial disclosures. Our curated collection ensures efficient tracking of BPMC's precision medicine developments without promotional bias.
Key focus areas include oncology pipeline updates, rare disease therapy approvals, and research collaborations. Content is rigorously organized to help users quickly identify material events impacting the company's trajectory in genomic medicine.
Bookmark this page for streamlined monitoring of Blueprint Medicines' progress in developing therapies that address abnormal kinase activity through innovative small molecule inhibitors. Check regularly for authoritative reporting on developments directly from corporate communications and validated sources.
Blueprint Medicines (NASDAQ: BPMC) has scheduled its first quarter 2025 financial results announcement and corporate update for Thursday, May 1, 2025, at 8:00 a.m. ET. The company will host a live conference call and webcast for this presentation.
Participants can access the conference call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) with conference ID 082088. A webcast will be available in the Investors & Media section of Blueprint Medicines' website, remaining accessible for 30 days after the call.
Blueprint Medicines (NASDAQ: BPMC) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Monday, April 7, 2025, at 12:45 p.m. ET.
Investors and interested parties can access a live webcast of the presentation through Blueprint Medicines' website's Investors & Media section. The presentation recording will remain accessible on the company's website for 30 days following the event.
Blueprint Medicines (BPMC) presented comprehensive data on its mast cell therapy portfolio at the 2025 AAAAI/WAO Joint Congress, featuring 14 presentations. The company showcased three-year median follow-up data from the PIONEER trial for AYVAKIT® (avapritinib) in indolent systemic mastocytosis (ISM) treatment.
Key findings demonstrate that AYVAKIT 25mg daily was well-tolerated with no new safety signals after 3 years of exposure. The treatment showed sustained symptom improvements and quality-of-life benefits. Notable results include:
- 93% of patients showed improved or stable benefits in overall symptoms
- Positive impact on bone density improvements
- Successful treatment outcomes even in patients without detectable KIT D816V mutations
Additionally, the company reported positive Phase 1 data for BLU-808, their investigational oral wild-type KIT inhibitor. The healthy volunteer trial showed the drug was well-tolerated with no serious adverse events, achieving dose-dependent serum tryptase reductions exceeding 80%. Multiple proof-of-concept trials are being initiated with initial data expected later in 2025.
Blueprint Medicines (NASDAQ: BPMC) reported strong financial results for Q4 and full year 2024. The company achieved $479.0 million in AYVAKIT global net product revenues in 2024, including $144.1 million in Q4. For 2025, Blueprint projects AYVAKIT revenues of $680-710 million, representing 45% year-over-year growth at midpoint.
The company updated its peak systemic mastocytosis franchise revenue opportunity to $4 billion, with AYVAKIT expected to reach $2 billion in revenue by 2030. The Q4 2024 net loss was $50.0 million, improving from a $110.9 million loss in Q4 2023. Cash position strengthened to $863.9 million as of December 31, 2024.
Blueprint plans to initiate proof-of-concept studies for BLU-808 in 2025 and will present 14 abstracts at the 2025 AAAAI/WAO Joint Congress, including three-year AYVAKIT safety and efficacy data.
Blueprint Medicines (NASDAQ: BPMC) has announced it will host a live conference call and webcast to report its fourth quarter and full year 2024 financial results on Thursday, February 13, 2025, at 8:00 a.m. ET. The company will also provide a corporate update during the event.
Investors can access the conference call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) with conference ID 349846. A webcast will be available on the company's investor relations website, with an archived version accessible for 30 days after the call.
Blueprint Medicines (BPMC) has updated its peak systemic mastocytosis (SM) franchise revenue opportunity to $4 billion, with expectations to achieve $2 billion in AYVAKIT revenue by 2030. The company projects AYVAKIT product revenue of $475-480 million for full-year 2024, representing over 130% growth from 2023.
The company announced positive Phase 1 trial results for BLU-808, their oral wild type KIT inhibitor. The drug demonstrated strong safety profile with only Grade 1 adverse events, and showed significant tryptase reductions up to 87% at the 12mg dose. The trial included both single-ascending dose (n=56) and multiple-ascending dose (n=31) studies.
Blueprint has initiated the Phase 3 HARBOR trial of elenestinib for indolent systemic mastocytosis (ISM) and is advancing CDK2 and CDK4 targeted protein degraders while de-prioritizing the BLU-222 program.
Blueprint Medicines (BPMC) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Kate Haviland will deliver a corporate overview and present the company's 2025 outlook on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET).
The presentation will be accessible through a live webcast on the Investors & Media section of Blueprint Medicines' website. Interested parties can access the replay, which will remain available on the company's website for 30 days after the presentation.
Blueprint Medicines (BPMC) presented data at the 2024 ASH Annual Meeting demonstrating long-term clinical benefits of AYVAKIT (avapritinib) in advanced systemic mastocytosis (SM). Key findings include significant survival benefits in treatment-naïve patients compared to midostaurin, sustained improvements in bone density for patients with low bone mass, and evidence of immune dysregulation in indolent SM patients.
The company also highlighted a new ultra-sensitive KIT testing method in peripheral blood that identified previously undetected KIT mutations in PIONEER trial patients, suggesting SM may be more prevalent than previously thought. Additionally, Blueprint developed a machine learning model to distinguish between advanced SM and ISM, validated by Dana-Farber Cancer Institute data.
Blueprint Medicines (BPMC) reported strong Q3 2024 financial results, achieving $128.2 million in AYVAKIT net product revenues, representing 136% growth year-over-year. The company raised its full-year 2024 AYVAKIT revenue guidance to $475-480 million, up from previous guidance of $435-450 million. Q3 net loss was $56.3 million, improved from $133.7 million in Q3 2023. Cash position strengthened to $882.4 million as of September 30, 2024. The company expects declining operating expenses and cash burn in 2024 compared to 2023, while maintaining focus on long-term growth.
FAQ
What is the current stock price of Blueprint Medicines (BPMC)?
What is the market cap of Blueprint Medicines (BPMC)?
